SillaJen, Inc.’s Anticancer Virus ‘SJ-650’ Selected for National New Drug Development Project… Moving Forward with Preclinical Trials
Anti-cancer virus capable of repeated intravenous administration developed… Support provided for establishing manufacturing process
Evading the Immune Response via the CD55 Protein… Anticancer Effects Confirmed in Animal Models of Metastatic Cancer
[Edaily Reporter NA EUN-KYUNG ] SillaJen, Inc.(215600)The company is receiving government support for the development of “SJ-650,” a next-generation anticancer viral therapy administered via intravenous injection. It plans to accelerate the development of this new drug, which overcomes the immune response within the body—a limitation of existing anticancer viruses—and is capable of treating metastatic cancer.
SillaJen, Inc. announced on the 18th that SJ-650 has been selected as a supported project under the National New Drug Development Program administered by the National New Drug Development Project Group. The company plans to use this funding to develop manufacturing processes and conduct follow-up research, including preclinical safety evaluations.
The National New Drug Development Project is a cross-ministerial R&D initiative launched in 2021 to provide support for a 10-year period, covering everything from the discovery of new drug candidates to clinical development. Through this project, SillaJen, Inc. aims to establish the manufacturing process for SJ-650 and lay the groundwork necessary for advancing to the preclinical stage.
SJ-650 is an anticancer drug candidate that utilizes a genetically recombinant vaccinia virus. Oncolytic viruses are a therapeutic approach in which the virus penetrates and replicates within cancer cells, destroying them and inducing immune cells to attack the tumor.
“Imlygic,” an oncolytic virus therapy currently approved in the United States, is injected directly into melanoma lesions. In contrast, SJ-650 is designed to be administered intravenously for systemic delivery. This is to enable its use against cancers located deep within organs—where direct injection into the tumor is difficult—as well as metastatic cancers.
The biggest challenge with this intravenous administration method is the body’s immune response. This is because the virus can be eliminated by complement proteins and neutralizing antibodies in the blood before it reaches the cancer tissue, and the therapeutic effect may diminish if neutralizing antibodies form during repeated administrations. To address this, SillaJen, Inc. designed the virus to express “CD55,” a human-derived complement regulatory protein, on its surface. The principle is that CD55 inhibits complement-mediated viral elimination and also blocks access by neutralizing antibodies.
The results of this research were published last May in the international journal *Molecular Therapy*. A research team from Seoul National University College of Medicine and SillaJen, Inc. researchers confirmed SJ-650’s tumor growth-inhibiting effects in animal models of metastatic cancer. Antibody evasion was also observed in patient-derived serum containing neutralizing antibodies against the vaccinia virus.
SillaJen, Inc. previously conducted a Phase 3 clinical trial of “Pexa-Vec,” a vaccinia virus-based anticancer drug, for liver cancer but terminated the trial early in 2019 following a futility analysis. SJ-650 is a separate candidate compound designed to express CD55 on the virus surface to enhance the efficacy of systemic and repeated administration.
However, the anticancer efficacy of SJ-650 has only been confirmed in preclinical studies, and its safety and efficacy in actual patients have not yet been verified. SillaJen, Inc. plans to proceed with manufacturing and quality control (CMC) development and preclinical trials, while also exploring opportunities for joint development and technology transfer with global pharmaceutical companies.
A SillaJen, Inc. official stated, “Being selected for the National New Drug Development Project has enabled us to fully ramp up R&D on SJ-650,” adding, “We will proceed smoothly with the development of the candidate compound and manufacturing process to lay the groundwork for advancing to subsequent development stages.”
“The bond market should be a universal channel for corporate financing, but right now it’s like an exclusive social club.”This was the point raised by an advisory committee member during a meeting hel…
KYOCHON FOOD&BEVERAGE, operator of the Kyochon Chicken franchise, is expanding its sales channels for traditional Korean liquor by introducing its premium makgeolli, “Eunhwasu: A Night of Stargazing 1…
SillaJen, Inc.(215600)The company is receiving government support for the development of “SJ-650,” a next-generation anticancer viral therapy administered via intravenous injection. It plans to accele…